NEW YORK (GenomeWeb) – Bio-Techne has signed a deal to gain access to B-MoGen Biotechnologies' gene-editing technology, the companies announced today. As part of the arrangement, Bio-Techne has also made an unspecified seed investment in B-MoGen.

Specific details about the technology were not disclosed, but B-MoGen offers genome modification services that use targeted nucleases to delete genes, exons, or genomic regions, or to insert specific sequences into the genome. The company has also filed a patent application on a single-step method for isolating gene-edited cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.